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Abstract
Outcome-driven recommendations about time intervals during which ambulatory blood pressure 
should be measured to diagnose white-coat or masked hypertension are lacking. We cross-
classified 8237 untreated participants (mean age, 50.7 years; 48.4% women) enrolled in 12 
population studies, using ≥140/≥90, ≥130/≥80, ≥135/≥85, and ≥120/≥70 mm Hg as hypertension 
thresholds for conventional, 24-hour, daytime, and nighttime blood pressure. White-coat 
hypertension was hypertension on conventional measurement with ambulatory normotension, the 
opposite condition being masked hypertension. Intervals used for classification of participants 
were daytime, nighttime, and 24 hours, first considered separately, and next combined as 24 hours 
plus daytime or plus nighttime, or plus both. Depending on time intervals chosen, white-coat and 
masked hypertension frequencies ranged from 6.3% to 12.5% and from 9.7% to 19.6%, 
respectively. During 91 046 person-years, 729 participants experienced a cardiovascular event. In 
multivariable analyses with normotension during all intervals of the day as reference, hazard ratios 
associated with white-coat hypertension progressively weakened considering daytime only (1.38; 
P=0.033), nighttime only (1.43; P=0.0074), 24 hours only (1.21; P=0.20), 24 hours plus daytime 
(1.24; P=0.18), 24 hours plus nighttime (1.15; P=0.39), and 24 hours plus daytime and nighttime 
(1.16; P=0.41). The hazard ratios comparing masked hypertension with normotension were all 
significant (P<0.0001), ranging from 1.76 to 2.03. In conclusion, identification of truly low-risk 
white-coat hypertension requires setting thresholds simultaneously to 24 hours, daytime, and 
nighttime blood pressure. Although any time interval suffices to diagnose masked hypertension, as 
proposed in current guidelines, full 24-hour recordings remain standard in clinical practice.
Keywords
ambulatory blood pressure monitoring; cardiovascular risk; masked hypertension; population 
science; white-coat hypertension
Ambulatory blood pressure should be offered to those with elevated conventional blood 
pressure.1,2 White-coat hypertension is a condition, characterized by an elevated blood 
pressure on conventional office measurement, but a normal ambulatory blood pressure 
outside the medical environment. Conversely, masked hypertension is a normal blood 
pressure on conventional measurement accompanied by an elevated blood pressure on 
ambulatory monitoring.
To define white-coat and masked hypertension, guidelines1–5 and previous studies6,7 have 
applied varying thresholds during different periods of the day, which have included systolic/
diastolic blood pressure thresholds of ≥130/≥80 mm Hg for the 24-hour blood pressure, 
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≥135/≥85 mm Hg for the daytime or awake blood pressure, and ≥120/≥70 mm Hg for the 
nighttime or asleep blood pressure.2,4,5 There is no firm recommendation on how to 
maximize discrimination of risk among patients with white-coat and masked hypertension 
by applying the aforementioned thresholds to 24-hour, daytime, or nighttime blood pressure 
levels or combinations of these intervals.2 To address this issue, we did a participant-level 
meta-analysis among 8237 people recruited from 12 populations and enrolled in the 
International Database on Ambulatory Blood Pressure in Relation to Cardiovascular 
Outcomes (IDACO). We determined the long-term outcome associated with white-coat 
hypertension and masked as defined from ambulatory blood pressure thresholds applied 
during varying periods of the day.
Methods
Study Population
Previous publications have described the construction of the IDACO database in detail.8 
Studies qualified for inclusion if they involved a random population sample, if baseline 
information on the conventional and ambulatory blood pressures and cardiovascular risk 
factors was available, and if subsequent follow-up included both fatal and nonfatal 
outcomes. All studies received ethical approval and adhered to the principles of the 
Declaration of Helsinki, and participants gave written informed consent.
The IDACO database8 currently includes 12 752 people representing 12 randomly recruited 
population cohorts9–18 with validated information on outcome. Exclusion criteria were as 
follows: (1) age <18 years (n=303), (2) conventional blood pressure unavailable (n=248), (3) 
nighttime blood pressure not recorded (n=1391),10 (4) being on antihypertensive drug 
treatment at baseline (n=2152), and (5) ambulatory blood pressure recordings not complying 
with predefined8 quality standards, including <10 daytime or <5 nighttime readings (n=421). 
The number of participants statistically analyzed was 8237 (Figure S1 in the online-only 
Data Supplement).
Cross-Classification Based on Conventional and Ambulatory Blood Pressure
Previous publications19,20 and the expanded Methods available in the online-only Data 
Supplement provide detailed information on conventional and ambulatory blood pressure 
measurement and on the anthropometric and biochemical measurements performed at 
baseline.
Conventional hypertension was a conventional blood pressure of 140 mm Hg systolic or 90 
mm Hg diastolic or more.5 Ambulatory hypertension was a 24-hour level of 130 mm Hg 
systolic or 80 mm Hg diastolic or more; for the daytime blood pressure these thresholds 
were 135 and 85 mm Hg and for the nighttime blood pressure 120 and 70 mm Hg, 
respectively.5 Normotension and sustained hypertension were consistently normal or 
elevated levels on both conventional and ambulatory blood pressures (Figure S2). White-
coat hypertension was defined as conventional hypertension in the presence of a normal 
ambulatory blood pressure. Masked hypertension was defined as ambulatory hypertension in 
participants with a normal conventional blood pressure. When systolic or diastolic blood 
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pressure was in a different category (normotensive versus hypertensive), we considered the 
participant as hypertensive. Table S1 lists the thresholds and intervals used for the cross-
classification of participants. For ambulatory time intervals including nested periods (24 
hours±daytime±nighttime), the interval with the highest blood pressure classification 
(normotensive versus hypertensive) determined the ambulatory blood pressure status.
Ascertainment of Events
We ascertained vital status and the incidence of fatal and nonfatal diseases from the 
appropriate sources in each country, as described in detail in previous publications.19,20 
Outcomes were coded according to the International Classification of Diseases (ICD). Fatal 
and nonfatal stroke (ICD-Eighth/Ninth Revsion [8/9] 430–434 and 436, ICD-10 I60–I64 and 
I67–I68) did not include transient ischemic attacks. Coronary events encompassed death 
from ischemic heart disease (ICD-8 411–412, ICD-9 411 and 414, and ICD-10 I20, I24–
I25), sudden death (ICD-8 427.2 and 795, ICD-9 427.5 and 798, and ICD-10 I46 and R96), 
nonfatal myocardial infarction (ICD-8/9 410 and ICD-10 I21–I22), and coronary 
revascularization. Cardiac events comprised coronary end points and fatal and nonfatal heart 
failure (ICD-8 428, 427.1, 427.2, and 429; ICD-9 429 and ICD-10 I50 and J81). The 
diagnosis of heart failure required admission to hospital in the 3 cohorts.9–11 In the other 
cohorts, heart failure was either a clinical diagnosis or the diagnosis on the death certificate. 
However, in all cases the event was validated against hospital files or records held by family 
doctors. The cardiovascular end point included all aforementioned end points plus 
cardiovascular mortality (ICD-8 390–448, ICD-9 390.0–459.9, and ICD-10 I00 to I79 and 
R96). In all outcome analyses, we only considered the first event within each category.
Statistical Analysis
For database management and statistical analysis, we used SAS software, version 9.3 (SAS 
Institute Inc, Cary, NC). We compared mean values and proportions using the standard 
normal z test for large samples or ANOVA and the χ2-statistic, respectively. We used 
McNemar–Bowker test for the pairwise comparison of proportions. After stratification for 
cohort and sex, we interpolated missing values of body mass index (n=8) and total serum 
cholesterol (n=611) from the regression slope on age. In participants with unknown smoking 
(n=22), drinking (n=384), history of cardiovascular disease (n=1), or diabetes mellitus 
(n=3), we set the design variable to the cohort- and sex-specific mean of the codes (0, 1). 
Statistical significance was an α-level of ≤0.05 on 2-sided tests.
We calculated incidence rates in each category while standardizing by the direct method for 
sex and age (<40, 40–59, and ≥60 years). We used stratified Cox models to account for the 
heterogeneity of baseline hazards among cohorts and adjusted for sex, age, body mass index, 
smoking and drinking, total cholesterol, history of cardiovascular disease, and diabetes 
mellitus. Unless otherwise indicated, we used normotension as the reference group (hazard 
ratio, 1).
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Results
Baseline Characteristics
Of 8237 participants, 3986 (48.4%) were women, 2438 (29.7%) were current smokers, 455 
(5.5%) had diabetes mellitus, and 650 (7.9%) had a history of cardiovascular disease. Age 
averaged 50.7 (SD, 15.8) years. In all participants, the conventional blood pressure averaged 
128.8 (21.6) mm Hg systolic and 78.6 (11.3) mm Hg diastolic. The corresponding 
ambulatory blood pressure levels were 122.1 (13.6) and 73.1 (8.2) mm Hg in 24-hour, 128.5 
(14.5) and 78.3 (8.9) mm Hg in daytime recordings, and 111.0 (14.5) and 64.0 (9.0) mm Hg 
in nighttime, respectively. The median (5th–95th percentile interval) numbers of readings 
averaged to estimate the 24-hour, daytime, and nighttime blood pressure were 55 (35–82), 
28 (15–42), and 11 (6–13), respectively.
Table 1 lists the baseline characteristics by 4 categories according to the cross-classification 
of conventional and 24-hour ambulatory blood pressure. The differences across the 4 
categories were significant for all variables listed (P<0.0001).
Prevalence of White-Coat, Masked, and Sustained Hypertension
Based on the cross-classification between conventional and 24-hour ambulatory blood 
pressure (Table 1), 4988 participants (60.6%) were normotensive and 881 (10.7%), 800 
(9.7%), and 1568 (19.0%) had white-coat, masked, and sustained hypertension, respectively. 
Using different time intervals during which ambulatory blood pressure thresholds were 
applied substantially affected the estimates of prevalence (Table 2). They ranged from 
50.7% to 60.6% for normotension, from 6.3% to 12.5% for white-coat hypertension, from 
9.7% to 19.6% for masked hypertension, and from 17.3% to 23.5% for sustained 
hypertension. The prevalence of normotension and white-coat hypertension was lowest and 
the prevalence of masked and sustained hypertension was highest based on thresholds set 
simultaneously to the 24-hour and the daytime and nighttime blood pressures (Table 2). 
Table 3 summarizes reclassification rates of participants with white-coat and masked 
hypertension from the commonly used definitions based on daytime, nighttime, or 24-hour 
ambulatory blood pressure to one of the other definitions.
Incidence of Events
In the overall study population, median follow-up was 11.1 years (5th–95th percentile 
interval, 2.5–18.2 years). During 91 046 person-years of follow-up, 906 participants died 
(10.0 per 1000 person-years) and 729 participants experienced a fatal or nonfatal 
cardiovascular event (8.2 per 1000 person-years). Considering cause-specific first 
cardiovascular events, the incidence of cardiac events and stroke amounted to 473 and 242, 
respectively. More details on the incidence of end points are available in the Results in the 
online-only Data Supplement.
Risk of a Cardiovascular Event Associated With White-Coat Hypertension
Table 4 provides risk estimates by varying time intervals during which the ambulatory blood 
pressure thresholds were applied. Although accounting for cohort, sex, age, body mass 
index, smoking, drinking, total serum cholesterol, history of cardiovascular disease, and 
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diabetes mellitus (Table 4), white-coat hypertension based on daytime blood pressure 
compared with daytime normotension as well as that based on nighttime blood pressure 
compared with nighttime normotension carried significantly elevated risks of 30% 
(P≤0.048). Defining white-coat hypertension based on the 24-hour blood pressure with or 
without accounting for the daytime or nighttime blood pressure or both weakened the risk 
compared with normotension during the same periods to a nonsignificant level ranging from 
27% (P=0.097) for 24-hour plus daytime blood pressure to 9% (P=0.55) for 24-hour plus 
nighttime blood pressure. Irrespective of the ambulatory blood pressure time intervals used 
to cross-classify participants, the linear trend in the hazard ratios from normotension over 
white-coat and masked hypertension to sustained hypertension was consistently significant 
(P<0.0001).
In Table 4, the normotensive reference group differed according to the time intervals 
considered. In a further step of the analysis, we applied the most stringent definition of 
normotension as unique reference (Figure 1). This definition required that the conventional 
blood pressure was normal and that the 24-hour, daytime, and nighttime ambulatory blood 
pressures were within normal limits. The hazard ratios for white-coat hypertension versus 
normotension weakened from 1.38 for daytime only to 1.16 for 24 hours plus daytime and 
nighttime. Conversely, applying the most stringent definition of hypertension (Figure 2) 
showed that the risk of white-coat hypertension was consistently lower than that of sustained 
hypertension (P<0.0001) with hazard ratios decreasing from 0.57 for daytime to 0.45 for 24 
hours plus daytime and nighttime.
Risk of a Cardiovascular Event Associated With Masked Hypertension
In multivariable-adjusted analyses (Table 4), the risk associated with masked hypertension 
compared with normotension was always highly significant (P≤0.0001) with estimates of 
excess risk ranging from 61% to 81%. Applying the most stringent definition of 
normotension (Figure 1) confirmed that the hazard ratios comparing masked hypertension 
with normotension were all significant (P<0.0001), between 1.76 and 2.03. Conversely, 
applying the most stringent definition of hypertension (Figure 2) showed that the risk of 
masked hypertension was lower than that of sustained hypertension (P≤0.0074). The hazard 
ratios were essentially similar, from 0.61 to 0.70.
Risk of Other End Points Associated With White-Coat and Masked Hypertension
Results for total and cardiovascular mortality, fatal and non-fatal cardiac events, and stroke
—equivalent to those given for the composite cardiovascular end point in Table 4—are 
provided in Table S2. In analyses with normotension as reference and adjusted as before, 
white-coat hypertension did not confer a formally significantly elevated risk (P≥0.051) 
except for the risk of stroke based on a nighttime-derived definition of white-coat 
hypertension (P=0.0065).
Masked hypertension was a significant predictor (P≤0.023) of all end points with the 
exception of all-cause mortality if the diagnosis was derived from the daytime blood 
pressure, 24-hour blood pressure, or 24-hour plus daytime blood pressure (P≥0.059).
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Discussion
Current guidelines for ambulatory blood pressure monitoring or for the management of 
hypertension do not provide outcome-driven evidence for defining the time windows during 
which the ambulatory blood pressure should be measured to define white-coat and masked 
hypertension in an accurate manner. Depending on the definition, frequencies of white-coat 
and masked hypertension ranged from 6.3% to 12.5% and from 9.7% to 19.6%, respectively. 
Furthermore, the risk associated with white-coat hypertension decreased when a more 
stringent definition of ambulatory normotension was used. Finally, ambulatory hypertension 
during any time interval predicted an ≈2-fold higher cardiovascular risk in patients with 
masked hypertension.
During the past decade, European guidelines5,21,22 have proposed changing or twin 
thresholds for ambulatory hypertension without providing any solid justification in terms of 
outcome data. The 2003 guideline only recommended a threshold for the 24-hour 
ambulatory blood pressure of ≥125/≥80 mm Hg.21 The 2007 guideline proposed as 
thresholds for the 24-hour, daytime, and nighttime blood pressure levels of ≥125 to 130/≥80, 
≥130 to 135/≥85, and ≥120/≥70 mm Hg, respectively.22 The 2013 guideline5 removed the 
ambiguity in the thresholds for the 24-hour and daytime blood pressure, recommending 
≥130/≥80 and ≥135/≥85 mm Hg, respectively, whereas keeping the nighttime threshold at 
≥120/≥70 mm Hg. In a 2007 analysis of the IDACO database,6 we determined thresholds for 
the ambulatory blood pressure, which yielded 10-year cardiovascular risks similar to those 
associated with optimal (120/80 mm Hg), normal (130/85 mm Hg), and high (140/90 mm 
Hg) blood pressure on conventional measurement. After rounding, approximate thresholds 
for an optimal ambulatory blood pressure amounted to 115/75 mm Hg for 24 hours, 120/80 
mm Hg for daytime, and 100/65 mm Hg for nighttime. Rounded thresholds for a normal 
ambulatory blood pressure were 125/75, 130/85, and 110/70 mm Hg, respectively, and those 
for ambulatory hypertension were 130/80, 140/85, and 120/70 mm Hg.
Whether white-coat hypertension substantially elevates cardiovascular risk continues to 
divide expert opinion. In a meta-analysis of summary statistics from 4 prospective cohorts, 
the pooled hazard ratio for stroke associated with white-coat hypertension defined by a 
daytime blood pressure threshold of 130/80 mm Hg became comparable with that in 
ambulatory hypertension group by the ninth year of follow-up.23 However, the median 
follow-up of the 4 cohorts was only 5.4 years, and the pooled hazard ratio was not 
adjusted.23 The risk in white-coat hypertension was not significantly different from that in 
normotension when multivariable-adjusted models were applied.12,24,25 In the meta-analysis 
by Pierdomenico and Cuccurullo,25 5 of the 7 eligible studies applied a daytime blood 
pressure threshold of 135/85 mm Hg, whereas 2 other studies either applied a daytime 
threshold ranging from 131 to 136 mm Hg26 or a 24-hour blood pressure cut off of 130/80 
mm Hg.27 In a previous IDACO publication,28 we included both treated and untreated 
participants. In this analysis, we classified treated people according to the achieved 
ambulatory blood pressure.28 Compared with normotension, the risk of all cardiovascular 
and cause-specific cardiovascular complications was not increased, irrespective of whether 
we used 130/80 or 135/85 mm Hg as cutoff threshold for the daytime blood pressure 
(0.63≥P≥0.09).28 Subsequently, Franklin et al,24 using the IDACO database, reported that in 
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treated subjects with isolated systolic hypertension, the cardiovascular risk was similar in 
elevated conventional and normal daytime systolic blood pressure as compared with those 
with normal conventional and normal daytime blood pressure (P=0.57). However, both 
treated patients with isolated systolic hypertension and white-coat hypertension and treated 
participants with normal blood pressure had an ≈2-fold increased cardiovascular risk when 
compared with untreated normotensive people.24 Summarizing the evidence of previous 
studies,26 it is clear that the long-term white-coat hypertension carries an increased risk and 
that the prognostic meaning of white-coat hypertension differs among treated and untreated 
subjects. What our current study adds to the knowledge on white-coat hypertension26 is that 
to identify the low-risk subjects among untreated people with white-coat hypertension, full 
24-hour ambulatory recordings are required and the most stringent definition of ambulatory 
normotension, with thresholds applied to the whole ambulatory recording including daytime 
and nighttime, has to be applied. Although in our study the risk of white-coat hypertension, 
as defined using the most stringent definition, was not significantly different from the risk in 
sustained normotension, we cannot definitely exclude that this definition of white-coat 
hypertension is not associated with increased risk. Further analyses in large population 
cohorts applying the same stringent definition of white-coat hypertension are needed to 
confirm our findings.
In contrast to white-coat hypertension,12,26,27,29–31 the current literature by and large 
supports the view that masked hypertension carries a risk only slightly lower than or equal to 
sustained hypertension,28,32 irrespective of treatment status. The Finn-Home Study 
Investigators33 are in agreement with IDACO findings,28 demonstrating that high-normal 
systolic and diastolic conventional blood pressure, older age, greater body mass index, 
current smoking, and diabetes mellitus are independent determinants of masked 
hypertension. Similarly, Franklin et al32 reported that among people not being treated for 
hypertension, the prevalence of masked hypertension, using a daytime ambulatory threshold 
of 135/85 mm Hg, was higher in diabetic than in nondiabetic participants (18.1% versus 
13.8%). Moreover, we previously reported that masked hypertension, as diagnosed by 
ambulatory34 or home35 blood pressure monitoring, leads to an ≈2-fold increase in the risk 
of cardiovascular events or stroke in people with an optimal or normal conventional blood 
pressure. What our current study adds to the knowledge on blood pressure is that ambulatory 
hypertension during any part of the day reliably identifies this high-risk condition.
Our current study must be interpreted within the context of some potential limitations. First, 
conventional blood pressure was the average of only 2 readings obtained at a single 
examination, which might not have been sufficient to remove the white-coat effect. Second, 
we have no information on anti-hypertensive drug treatment after the baseline visit at 
enrolment. Third, the current IDACO participants were recruited from 12 geographically 
areas with different life styles and healthcare delivery systems. Study protocols and 
definition of events were cohort specific. However, we accounted for these differences in 
methodology among cohorts by including center as stratification variable in the Cox 
proportional hazard models. Finally, ambulatory blood pressure monitoring was not 
standardized in terms of device type and intervals between readings. However, using a 
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single SAS macro ensured that the time-weighted mean values during all periods of the day 
were calculated identically across cohorts.
Our current study has important clinical implications and may inform future guidelines. 
From a clinical point of view, our findings highlight that to identify individuals at low risk 
of cardiovascular complications among untreated participants with white-coat hypertension, 
full 24-hour ambulatory recordings are necessary with thresholds set during the whole 
recording period including daytime and nighttime. Conversely, to diagnose masked 
hypertension, ambulatory hypertension during any period of the day might be sufficient with 
a slight difference in the predictive accuracy. Furthermore, among 8237 untreated IDACO 
participants, 747 (9.1%) and 881 (10.7%) had white-coat hypertension based on the 24-hour 
or daytime blood pressure according to the current guidelines,2,5 but only 515 (6.3%) had 
the low-risk variant as defined in our current report.
Perspectives
To identify patients with white-coat hypertension with a cardiovascular risk similar to that of 
normotensive people, one needs full 24-hour ambulatory recordings with thresholds set to all 
recording intervals, including daytime and nighttime. The definition in current guidelines of 
truly low-risk white-coat hypertension is therefore not precise enough. To diagnose masked 
hypertension, ambulatory hypertension during any period of the day is sufficient with a 
slight difference in predictive accuracy. Current guidelines therefore accurately cover the 
definition of masked hypertension. The difference between white-coat and masked 
hypertension in terms of time intervals during which blood pressure must be monitored is 
unexpected and novel. Our findings might inform expert committees writing guidelines so 
that arbitrary definitions are replaced by outcome-driven standards.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Novelty and Significance
What Is New?
• In 8237 untreated participants, we generated outcome-driven proposals about 
the time intervals during which the ambulatory blood pressure should be 
measured to diagnose truly low-risk white-coat hypertension and masked 
hypertension. White-coat hypertension was hypertension on conventional 
measurement with ambulatory normotension, the opposite condition being 
masked hypertension. Intervals used for classification of participants were 
daytime, nighttime, and 24 hours, first considered separately, and next combined 
as 24 hours plus daytime or plus nighttime or plus both.
What Is Relevant?
• To identify patients with white-coat hypertension who have a cardiovascular 
risk similar to that of normotensive people, one needs full 24-hour ambulatory 
recordings with thresholds set to all recording intervals, including daytime and 
nighttime. To diagnose masked hypertension, ambulatory hypertension during 
any period of the day is sufficient with only a slight increase in predictive 
accuracy, if the ambulatory blood pressure is consistently elevated for most of 
the day.
Summary
The difference between white-coat and masked hypertension in terms of time intervals 
during which blood pressure must be monitored was unexpected. These findings might 
inform guidelines so that outcome-driven standards replace arbitrary definitions and so 
that the management of white-coat hypertension is differentiated, based on the time 
interval of blood pressure monitoring used for its diagnosis.
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Figure 1. 
Risk of a cardiovascular end point associated with white-coat and masked hypertension vs 
stringently defined normotension defined by various intervals of ambulatory monitoring. 
Definition of the blood pressure cross-classifications is given in the Methods and in the 
footnote to Table 2. In this analysis, we applied the most stringent definition of 
normotension as unique reference in which the conventional blood pressure was normal and 
that the ambulatory blood pressure was within normal limits for 24 hours plus daytime and 
nighttime. Hazard ratios express the risk compared with normotension and were adjusted for 
sex, age, body mass index, smoking, drinking, total cholesterol, diabetes mellitus, history of 
cardiovascular disease, and cohort. Horizontal bars denote the 95% confidence interval of 
the hazard ratios.
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Figure 2. 
Risk of a cardiovascular end point associated with white-coat and masked hypertension vs 
stringently defined hypertension defined by various intervals of ambulatory monitoring. 
Definition of the blood pressure cross-classifications is given in the Methods and in the 
footnote to Table 2. In this analysis, we applied the most stringent definition of hypertension 
as unique reference in which the conventional blood pressure was over the threshold and 
that the ambulatory blood pressure was over the thresholds for 24 hours plus daytime and 
nighttime. Hazard ratios express the risk compared with hypertension and were adjusted for 
sex, age, body mass index, smoking, drinking, total cholesterol, diabetes mellitus, history of 
cardiovascular disease, and cohort. Horizontal bars denote the 95% confidence interval of 
the hazard ratios.
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Table 1
Baseline Characteristics of 8237 Untreated Participants Cross-Classified by Conventional and 24-Hour 
Ambulatory Blood Pressure
Characteristics Normotension White-Coat Hypertension Masked Hypertension Sustained Hypertension
No. of characteristics (%) 4988 881 800 1568
 Women 2767 (55.5) 404 (45.9)* 293 (36.6)* 522 (33.3)
 Current smoking 1544 (31.0) 168 (19.2)* 298 (37.3)* 428 (27.4)*
 Drinking alcohol 2304 (47.5) 381 (46.6) 458 (60.3)* 923 (64.6)†
 Diabetes mellitus 182 (3.6) 67 (7.6)* 57 (7.1) 149 (9.5)
 Previous cardiovascular diseases 237 (4.8) 126 (14.3)* 54 (6.8)* 233 (14.9)*
 Ethnicity (white) 4171 (83.6) 662 (75.3)* 641 (80.1)† 1294 (82.6)
Mean characteristic (SD)
 Age, y 45.7 (15.1) 59.3 (13.8)* 52.8 (14.0)* 60.8 (12.4)*
 Body mass index, kg/m2 24.3 (3.8) 26.0 (4.1)* 25.7 (4.0) 26.9 (4.4)*
 Total serum cholesterol, mmol/L 5.44 (1.15) 5.80 (1.26)* 5.68 (1.18)† 5.86 (1.16)*
Blood pressure
 Conventional systolic, mm Hg 117.0 (11.3) 148.4 (15.0)* 126.2 (8.9)* 156.7 (20.9)*
 Conventional diastolic, mm Hg 73.2 (7.9) 85.6 (9.4)* 78.7 (7.3)* 91.7 (10.4)*
 24-h systolic, mm Hg 114.7 (7.7) 121.4 (6.1)* 132.7 (7.7)* 140.8 (12.0)*
 24-h diastolic, mm Hg 69.3 (5.3) 71.7 (5.2)* 79.9 (5.8)* 82.6 (8.3)*
 Daytime systolic, mm Hg 121.0 (9.1) 128.0 (8.3)* 139.1 (10.0)* 147.2 (12.9)*
 Daytime diastolic, mm Hg 74.5 (6.3) 76.8 (7.0)* 84.9 (7.0)* 87.5 (9.4)*
 Nighttime systolic, mm Hg 104.1 (8.8) 109.7 (8.8)* 120.9 (10.7)* 128.8 (15.3)*
 Nighttime diastolic, mm Hg 60.2 (6.3) 62.8 (6.3)* 70.5 (7.4)* 73.4 (9.5)*
Values are number of participants (%) or arithmetic mean (SD). Thresholds for hypertension were ≥140/≥90 and ≥130/≥80 mm Hg on conventional 
and 24-hour ambulatory measurement, respectively. Normotension and sustained hypertension were consistently normal or elevated blood pressure 
on both conventional and 24-hour ambulatory measurement. White-coat hypertension had a raised conventional blood pressure and normal 24-hour 
blood pressure. Masked hypertension had an elevated 24-hour ambulatory blood pressure with normal conventional blood pressure. If for a type of 
measurement, systolic and diastolic blood pressures were in a different category, participants were classified as hypertensive. Smoking, drinking, 
diabetes mellitus, history of cardiovascular disease, body mass index, and cholesterol were unavailable in 22, 384, 3, 1, 8, and 611 participants, 
respectively.
Significance of the difference with the left adjacent column:
*
P<0.001 and
†
P<0.05.
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Table 2
Prevalence of Blood Pressure Categories According to Intervals of Ambulatory Monitoring
Intervals Used to Categorize the 
Ambulatory Blood Pressure Normotension White-coat Hypertension Masked Hypertension Sustained Hypertension
Daytime only 4683 (56.9) 747 (9.1) 1105 (13.4) 1702 (20.7)
Nighttime only 4806 (58.3) 1027 (12.5) 982 (11.9) 1422 (17.3)
24 h only 4988 (60.6) 881 (10.7) 800 (9.7) 1568 (19.0)
24 h plus daytime 4551 (55.3) 642 (7.8) 1237 (15.0) 1807 (21.9)
24 h plus nighttime 4572 (55.5) 724 (8.8) 1216 (14.8) 1725 (20.9)
24 h plus daytime and nighttime 4176 (50.7) 515 (6.3) 1612 (19.6) 1934 (23.5)
Values are number of participants (%). Normotension and sustained hypertension had consistently normal or elevated blood pressure levels on both 
conventional and ambulatory measurement. White-coat hypertension was defined as conventional hypertension in the presence of a normal 
ambulatory blood pressure. Masked hypertension was defined as ambulatory hypertension in participants with a normal conventional blood 
pressure. When systolic or diastolic blood pressure was in a different category (normotensive vs hypertensive), participant were classified as 
hypertensive. For ambulatory time intervals including nested periods (24 hours±daytime±nighttime), the interval with the highest blood pressure 
classification (normotensive vs hypertensive) determined the ambulatory blood pressure status.
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Table 4
Risk of Cardiovascular End Point by Intervals of Ambulatory Monitoring
Blood Pressure Cross-Classification E/R, n Rate (SE) Hazard Ratio (95% CI) P Value
Daytime
 Normotension 203/4683 6.0 (0.4) 1.00 …
 White-coat hypertension 92/747 9.7 (1.2) 1.30 (1.00–1.69) 0.048
 Masked hypertension 105/1105 8.8 (0.9) 1.61 (1.27–2.05) 0.0001
 Sustained hypertension 329/1702 13.7 (0.8) 2.14 (1.76–2.60) <0.0001
Nighttime
 Normotension 209/4806 5.9 (0.4) 1.00 …
 White-coat hypertension 121/1027 8.7 (0.9) 1.30 (1.03–1.64) 0.031
 Masked hypertension 99/982 9.6 (1.0) 1.71 (1.34–2.18) <0.0001
 Sustained hypertension 300/1422 15.4 (0.9) 2.40 (1.97–2.93) <0.0001
24 h
 Normotension 219/4988 5.9 (0.4) 1.00 …
 White-coat hypertension 98/881 8.3 (1.0) 1.20 (0.93–1.54) 0.16
 Masked hypertension 89/800 10.1 (1.1) 1.81 (1.41–2.32) <0.0001
 Sustained hypertension 323/1568 15.0 (0.9) 2.31 (1.91–2.80) <0.0001
24 h plus daytime
 Normotension 187/4551 5.7 (0.4) 1.00 …
 White-coat hypertension 74/642 9.0 (1.2) 1.27 (0.96–1.69) 0.097
 Masked hypertension 121/1237 9.1 (0.8) 1.72 (1.36–2.17) <0.0001
 Sustained hypertension 347/1807 13.7 (0.8) 2.23 (1.83–2.72) <0.0001
24 h plus nighttime
 Normotension 189/4572 5.7 (0.4) 1.00 …
 White-coat hypertension 70/724 7.3 (1.1) 1.09 (0.82–1.45) 0.55
 Masked hypertension 119/1216 9.2 (0.9) 1.67 (1.32–2.11) <0.0001
 Sustained hypertension 351/1725 14.8 (0.8) 2.35 (1.93–2.87) <0.0001
24 h plus daytime and nighttime
 Normotension 159/4176 5.5 (0.5) 1.00 …
 White-coat hypertension 50/515 7.7 (1.3) 1.13 (0.81–1.57) 0.47
 Masked hypertension 149/1612 8.8 (0.7) 1.70 (1.35–2.14) <0.0001
 Sustained hypertension 371/1934 13.8 (0.8) 2.34 (1.90–2.88) <0.0001
Definition of the blood pressure cross-classifications is given in the Methods and in the footnote to Table 2. Rates (SE) of events per 1000 person-
year were standardized by the direct method for sex and age. Hazard ratios (95% CI) express the risk compared with normotension and were 
adjusted for sex, age, body mass index, smoking, drinking, total cholesterol, diabetes mellitus, history of cardiovascular disease, and cohort. CI 
indicates confidence interval; and E/R, events/participants at risk.
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